Literature DB >> 28161243

Facial nerve paralysis associated with temporal bone masses.

Hironobu Nishijima1, Kenji Kondo2, Ryoji Kagoya2, Hitoshi Iwamura2, Kazuo Yasuhara2, Tatsuya Yamasoba2.   

Abstract

OBJECTIVE: To investigate the clinical and electrophysiological features of facial nerve paralysis (FNP) due to benign temporal bone masses (TBMs) and elucidate its differences as compared with Bell's palsy.
METHODS: FNP assessed by the House-Brackmann (HB) grading system and by electroneurography (ENoG) were compared retrospectively.
RESULTS: We reviewed 914 patient records and identified 31 patients with FNP due to benign TBMs. Moderate FNP (HB Grades II-IV) was dominant for facial nerve schwannoma (FNS) (n=15), whereas severe FNP (Grades V and VI) was dominant for cholesteatomas (n=8) and hemangiomas (n=3). The average ENoG value was 19.8% for FNS, 15.6% for cholesteatoma, and 0% for hemangioma. Analysis of the correlation between HB grade and ENoG value for FNP due to TBMs and Bell's palsy revealed that given the same ENoG value, the corresponding HB grade was better for FNS, followed by cholesteatoma, and worst in Bell's palsy.
CONCLUSIONS: Facial nerve damage caused by benign TBMs could depend on the underlying pathology. Facial movement and ENoG values did not correlate when comparing TBMs and Bell's palsy. When the HB grade is found to be unexpectedly better than the ENoG value, TBMs should be included in the differential diagnosis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bell palsy,; Electroneurography; Facial nerve paralysis; Schwannoma; Temporal bone tumor

Mesh:

Year:  2017        PMID: 28161243     DOI: 10.1016/j.anl.2016.12.006

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  1 in total

Review 1.  Surgical anatomy of the facial nerve: from middle cranial fossa approach to endoscopic approach. A pictorial review.

Authors:  Davide Soloperto; Flavia Di Maro; Beatrice Le Pera; Daniele Marchioni
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-12       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.